$ News

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

LAVA Announces Evaluation of Strategic Options

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.03

LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Underpin Buy Rating

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Therapeutics Shareholders Approve Key Resolutions

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024